--- title: "03:18 ETRosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA" type: "News" locale: "en" url: "https://longbridge.com/en/news/285679653.md" description: "Rosen Law Firm is investigating potential securities claims for shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) due to allegations of misleading business information. Investors who purchased ADMA securities may be eligible for compensation through a class action lawsuit. The investigation follows a report by short seller Culper Research, which claimed ADMA engaged in channel stuffing, leading to a 16.6% drop in stock price. Interested investors can contact the firm for more information on joining the class action." datetime: "2026-05-08T07:19:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285679653.md) - [en](https://longbridge.com/en/news/285679653.md) - [zh-HK](https://longbridge.com/zh-HK/news/285679653.md) --- # 03:18 ETRosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA , /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public. So What: If you purchased ADMA Biologics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case\_id=57940 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email \[email protected\] for information on the class action. What is this about: On March 24, 2026, Investing.com published an article entitled "ADMA Biologics shares plunge on short seller allegations." The article stated that ADMA Biologics shares fell "after short seller Culper Research released a report alleging the company engaged in channel stuffing to inflate revenue growth." On this news, ADMA Biologics stock fell 16.6% on March 24, 2026. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen\_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 \[email protected\] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. ### Related Stocks - [ADMA.US](https://longbridge.com/en/quote/ADMA.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) ## Related News & Research - [20:15 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA](https://longbridge.com/en/news/286483885.md) - [Neurothera Labs Announces Adoption of Semi-Annual Reporting](https://longbridge.com/en/news/287119698.md) - [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md) - [AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC](https://longbridge.com/en/news/286750290.md) - [BioMarin's drug shows significant growth gains in children in late-stage trial](https://longbridge.com/en/news/287121584.md)